|
| 37174087 | Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study. | | 2023 |
| 37772407 | Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1. | | 2023 |
| 37153702 | A Pilot Randomized Clinical Trial of Intranasal Oxytocin to Promote Weight Loss in Individuals With Hypothalamic Obesity. | J Endocr Soc | 2023 |
| 37460065 | Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population. | | 2023 |
| 37010875 | Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. | Neuro Oncol | 2023 |
| 36746138 | Updates in the Management of Central and Peripheral Nervous System Tumors among Patients with Neurofibromatosis Type 1 and Neurofibromatosis Type 2. | | 2023 |
| 37244583 | Retrospective Cohort Analysis of the Impact of Puberty on Plexiform Neurofibroma Growth in Patients with Neurofibromatosis Type 1. | | 2023 |
| 37115514 | Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. | Neuro Oncol | 2023 |
| 35262649 | Comparison of Visual Acuity Results Between ATS-HOTV and E-ETDRS Testing Methods in Children With Optic Pathway Gliomas. | Transl Vis Sci Technol | 2022 |
| 35657359 | Management of neurofibromatosis type 1-associated plexiform neurofibromas. | Neuro Oncol | 2022 |
| 35674741 | Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. | Genet Med | 2022 |
| 35788692 | MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. | Neuro Oncol | 2022 |
| 35535827 | Introduction. Evolving perspectives on the intersection between neurosurgery and neurocutaneous disorders. | Neurosurgical Focus | 2022 |
| 35849956 | Characteristics of Moyamoya Syndrome in Pediatric Patients With Neurofibromatosis Type 1. | Pediatr Neurol | 2022 |
| 35467749 | Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity. | Neuro Oncol | 2022 |
| 35235547 | Guideline for Children With Cancer Receiving General Anesthesia for Procedures and Imaging. | J Pediatr Hematol Oncol | 2022 |
| 34972035 | Atypical teratoid rhabdoid tumor in a child with neurofibromatosis type 2: A novel dual diagnosis. | Cancer Genet | 2022 |
| 35018469 | Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. | Neuro Oncol | 2022 |
| 34540703 | A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. | Front Oncol | 2021 |
| 31838937 | Cognition, ADHD Symptoms, and Functional Impairment in Children and Adolescents With Neurofibromatosis Type 1. | J Atten Disord | 2021 |
| 34125480 | Multi-institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. | Pediatr Blood Cancer | 2021 |
| 33585982 | Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). | Acta Neuropathol | 2021 |
| 34230196 | Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. | Neurology | 2021 |
| 34012067 | Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. | Genet Med | 2021 |
| 33631016 | A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. | Neuro Oncol | 2021 |
| 33507822 | NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. | J Clin Oncol | 2021 |
| 33502920 | Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. | J Clin Oncol | 2021 |
| 33336845 | Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. | Pediatr Blood Cancer | 2021 |
| 33405951 | Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). | J Clin Oncol | 2021 |
| 34678152 | Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. | Cancer Cell | 2021 |
| 34377779 | Impact of MEK Inhibitor Therapy on Neurocognitive Functioning in NF1. | Neurol Genet | 2021 |
| 34598159 | Arterial spin labeling as an ancillary assessment to postoperative conventional angiogram in pediatric moyamoya disease. | J Neurosurg Pediatr | 2021 |
| 32772175 | WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup? | Acta Neuropathol | 2020 |
| 31802236 | Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. | Acta Neuropathol | 2020 |
| 32187457 | Selumetinib in Children with Inoperable Plexiform Neurofibromas. | N Engl J Med | 2020 |
| 32236425 | A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. | Neuro Oncol | 2020 |
| 32055852 | Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. | Neuro Oncol | 2020 |
| 31865440 | Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. | Acta Neuropathol | 2020 |
| 32885166 | Predicting pediatric optic pathway glioma progression using advanced magnetic resonance image analysis and machine learning. | Neurooncol Adv | 2020 |
| 32642741 | Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations. | Neuro-Oncology Advances | 2020 |
| 32572180 | Late morbidity and mortality in adult survivors of childhood glioma with neurofibromatosis type 1: report from the Childhood Cancer Survivor Study. | Genet Med | 2020 |
| 33221469 | Visual field outcomes in children treated for neurofibromatosis type 1-associated optic pathway gliomas: a multicenter retrospective study. | J AAPOS | 2020 |
| 32502457 | Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. | Lancet Oncol | 2020 |
| 31532722 | Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1. | J Clin Oncol | 2019 |
| 31797581 | Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1. | Ann Clin Transl Neurol | 2019 |
| 31626572 | Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. | J Clin Oncol | 2019 |
| 30982198 | Clinical diagnosis of attention-deficit/hyperactivity disorder in survivors of pediatric brain tumors. | J Neurooncol | 2019 |
| 30908877 | First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics. | Am J Med Genet A | 2019 |
| 31363058 | Neurofibromatosis 2 in children presenting during the first decade of life. | Neurology | 2019 |
| 31151904 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. | Lancet Oncol | 2019 |